Omeros Corp (OMER): Marcia S. Kelbon , VP Patent and General Counsel of Omeros Corp sold 15,900 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $11.41 per share for a total value of $181,503.27 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 15,900 shares at $9.94 per share price.On Nov 20, 2015, Thomas J. Cable (director) sold 2,000 shares at $13.73 per share price.Also, On Sep 8, 2015, Peter A Md Demopulos (director) purchased 3,962 shares at $12.68 per share price.
Omeros Corporation: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Omeros Corporation which led to swings in the share price. The shares opened for trading at $11.23 and hit $11.69 on the upside , eventually ending the session at $11.3, with a gain of 1.53% or 0.17 points. The heightened volatility saw the trading volume jump to 3,32,789 shares. The 52-week high of the share price is $30.23 and the company has a market cap of $442 M . The 52-week low of the share price is at $8.9.
Company has been under the radar of several Street Analysts.Omeros Corporation is Initiated by Maxim Group to Buy and the brokerage firm has set the Price Target at $21. The Rating was issued on Jun 3, 2016.Omeros Corporation is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $21. The Rating was issued on Jun 3, 2016.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.